Obama appeals to lawmakers on drug research budget; Maryland preps stem cell grants; New cancer vax advance;

@FierceBiotech: Gamers tackle enzyme makeover, beat scientists' efforts. More | Follow @FierceBiotech

@JohnCFierce: 7% of teens and adults have HPV in their mouths, explaining steady rise in oropharyngeal cancer cases--LA Times. Article | Follow @JohnCFierce

@RyanMFierce: BioMarin ($BMRN) shows how stringing together small buyouts (~$20M) in rare diseases could lead to big rewards. More | Follow @RyanMFierce

@MarkHFierce: Researchers have reproduced Alzheimer's disease neurons, in a dish, using stem cells. Could be big research step. Story | Follow @MarkHFierce

> President Obama used the State of the Union address to appeal to lawmakers on a few issues near and dear to the biopharma industry. He called on Congress not to "gut" government spending on R&D, to create a better pathway to citizenship for foreign workers who come to the U.S. and work in labs here, and to improve the tax deduction for high-tech manufacturers. Story

> The Maryland Stem Cell Research Commission is preparing to hand out grants of up to $750,000 for preclinical and clinical-stage research programs in the state. Report

> Bayer AG is boosting its investment in Australia, with plans to add new workers. Story

Pharma News

@FiercePharma: NICE to have a "key role" in reviewing genetic tests in U.K., NHS says. News | Follow @FiercePharma

> Murdoch bows out of GSK board to focus on work. Article

And Finally... The research team at Trinity College Dublin says they have discovered a new approach for treating cancer based on manipulating the immune response to malignant tumors. Release

Suggested Articles

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.

Ex-Gilead CSO Norbert Bischofberger has struck a deal to buy a portfolio of spleen tyrosine kinase inhibitors from his former employer.